We are live on
!
Find out more
DY
Dowling & Yahnke Portfolio holdings
AUM
$2.15B
Turnover
6.98%
1-Year Est. Return
10.82%
This Fund
S&P 500
This Quarter
Est. Return
+20.41%
1 Year Est. Return
-10.82%
3 Year Est. Return
+34.82%
5 Year Est. Return
+71.23%
10 Year Est. Return
–
AUM
$1.19B
AUM Growth
+$154M
(+15%)
Cap. Flow
-$28.7M
Cap. Flow
% of AUM
-2.4%
Top 10 Holdings %
Top 10 Hldgs %
26.24%
Holding
314
New
23
Increased
125
Reduced
138
Closed
14
Avg Time Held Equity + Options
4.6
years
Top 10 Avg Time Held Equity + Options
2.8
years
Top 20 Avg Time Held Equity + Options
2.8
years
Avg Time Held Equity only
4.7
years
Top 10 Avg Time Held Equity only
2.8
years
Top 20 Avg Time Held Equity only
3
years
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
State Street Energy Select Sector SPDR ETF
XLE
|
+$3.21M |
| 2 |
Vanguard Emerging Markets Government Bond ETF
VWOB
|
+$1.99M |
| 3 |
Tesla
TSLA
|
+$1.03M |
| 4 |
Vanguard Global ex-US Real Estate ETF
VNQI
|
+$1.02M |
| 5 |
Otis Worldwide
OTIS
|
+$926K |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Qualcomm
QCOM
|
+$16.1M |
| 2 |
Vanguard Financials ETF
VFH
|
+$3.91M |
| 3 |
Vanguard Information Technology ETF
VGT
|
+$3.43M |
| 4 |
RTN
Raytheon Company
RTN
|
+$3.21M |
| 5 |
State Street SPDR S&P 500 ETF Trust
SPY
|
+$2.71M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Miscellaneous | 25.33% |
| 2 | Technology | 16.06% |
| 3 | Healthcare | 15.24% |
| 4 | Financials | 10.11% |
| 5 | Consumer Staples | 9.28% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
276
WisdomTree International SmallCap Dividend Fund
DLS
$1.04B
| $261K | 0.02% |
4,696
-20
| -0.4% | -$1.06K |
2013 Q2
28 quarters
|
|
277
iShares US Energy ETF
IYE
$1.79B
| $259K | 0.02% |
12,940
-66,160
| -84% | -$1.3M |
2019 Q4
2 quarters
|
|
278
iShares S&P Small-Cap 600 Value ETF
IJS
$7.51B
| $258K | 0.02% |
4,292
-86
| -2% | -$4.82K |
2013 Q2
28 quarters
|
|
279
iShares Russell Mid-Cap Value ETF
IWS
$15.4B
| $258K | 0.02% |
3,365
+46
| +1% | +$3.35K |
2013 Q4
26 quarters
|
|
280
iShares US Healthcare ETF
IYH
$4.17B
| $253K | 0.02% |
5,860
+235
| +4% | +$9.92K |
2018 Q4
6 quarters
|
|
281
iShares National Muni Bond ETF
MUB
$49.2B
| $251K | 0.02% |
+2,178
| New | +$247K |
2020 Q2
0 quarters
|
|
282
Air Products & Chemicals
APD
$66.7B
| $245K | 0.02% |
1,015
-73
| -7% | -$16.7K |
2019 Q2
4 quarters
|
|
283
iShares Russell 2000 Value ETF
IWN
$13.7B
| $245K | 0.02% |
+2,518
| New | +$229K |
2020 Q2
0 quarters
|
|
284
EOG Resources
EOG
$82.9B
| $239K | 0.02% |
4,722
-3,685
| -44% | -$179K |
2013 Q2
28 quarters
|
|
285
Intercontinental Exchange
ICE
$90.7B
| $235K | 0.02% |
+2,562
| New | +$235K |
2020 Q2
0 quarters
|
|
286
Schwab US Broad Market ETF
SCHB
$44.4B
| $235K | 0.02% |
+19,218
| New | +$222K |
2020 Q2
0 quarters
|
|
287
Motorola Solutions
MSI
$76.6B
| $232K | 0.02% |
1,656
-400
| -19% | -$56.6K |
2015 Q2
20 quarters
|
|
288
WEC Energy
WEC
$35.4B
| $224K | 0.02% |
2,553
-100
| -4% | -$9.02K |
2019 Q2
4 quarters
|
|
289
Edwards Lifesciences
EW
$49.9B
| $213K | 0.02% |
+3,081
| New | +$219K |
2020 Q2
0 quarters
|
|
290
Novartis
NVS
$286B
| $202K | 0.02% |
+2,308
| New | +$199K |
2020 Q2
0 quarters
|
|
291
Grifois
GRFS
$5.2B
| $200K | 0.02% |
10,955
| – | – |
2013 Q2
28 quarters
|
|
292
iShares S&P 500 Value ETF
IVE
$49.8B
| $200K | 0.02% |
1,850
-405
| -18% | -$43K |
2013 Q3
27 quarters
|
|
293
DELISTED
Chimerix, Inc.
CMRX
| $115K | 0.01% |
37,013
| – | – |
2019 Q3
3 quarters
|
|
294
DELISTED
Bristol-Myers Squibb Company Contingent Value Rights
BMY.RT
| $101K | 0.01% |
28,124
| – | – |
2019 Q4
2 quarters
|
|
295
Fortress Biotech
FBIO
$62.4M
| $54K | ﹤0.01% |
1,333
| – | – |
2019 Q1
5 quarters
|
|
296
BioCryst Pharmaceuticals
BCRX
$1.99B
| $52K | ﹤0.01% |
11,000
| – | – |
2020 Q1
1 quarter
|
|
|
TCON
297
DELISTED
TRACON Pharmaceuticals, Inc. Common Stock
TCON
| $40K | ﹤0.01% |
1,023
+273
| +36% | +$10.8K |
2020 Q1
1 quarter
|
|
|
ADMS
298
DELISTED
Adamas Pharmaceuticals
ADMS
| $33K | ﹤0.01% |
13,000
| – | – |
2019 Q3
3 quarters
|
|
299
Actinium Pharmaceuticals
ATNM
$35.5M
| $8K | ﹤0.01% |
762
| – | – |
2015 Q4
18 quarters
|
|
300
DELISTED
Regulus Therapeutics
RGLS
| $8K | ﹤0.01% |
+1,200
| New | +$7.85K |
2020 Q2
0 quarters
|
|
Similar funds
AC
APA
IC
SCA
ACM
W
Dowling & Yahnke's Q2 2020 Portfolio in Review
As of Q2 2020, Dowling & Yahnke held 314 positions worth $1.19B, up 15% from $1.04B the previous quarter. Its ten largest holdings account for 26% of the portfolio.
Dowling & Yahnke's Q2 2020 filing shows 23 new, 125 increased, 138 reduced and 14 closed positions. Its largest new stake was Otis Worldwide: 17,872 shares worth $1.02M. The largest sale was Qualcomm, an estimated $16.1M.
By sector, the portfolio is most concentrated in Miscellaneous at 25% of assets, down from 27% a quarter earlier, followed by Technology and Healthcare.
- Dowling & Yahnke's largest Q2 2020 buy was Otis Worldwide: 17,872 shares worth $1.02M.
- Dowling & Yahnke added most to State Street Energy Select Sector SPDR ETF in Q2 2020, an estimated $3.21M increase.
- Dowling & Yahnke's biggest Q2 2020 reduction was Qualcomm, cutting an estimated $16.1M.
- Dowling & Yahnke fully exited Raytheon Company in Q2 2020, selling an estimated $3.21M.
- Dowling & Yahnke's ten largest holdings make up 26% of its $1.19B portfolio in Q2 2020.
- Dowling & Yahnke opened 23 new positions and closed 14 in Q2 2020.
- Dowling & Yahnke's portfolio value rose 15% quarter-over-quarter to $1.19B.
Based on Dowling & Yahnke's 13F filing for Q2 2020, filed 31 Jul 2020.